Trial Outcomes & Findings for Covered vs Uncovered Metal Stents for Palliative Biliary Decompression in Inoperable Malignant Distal Bile Duct Obstruction (NCT NCT01905384)

NCT ID: NCT01905384

Last Updated: 2022-03-31

Results Overview

Compare the rate of long-term stent failure, defined as need for repeat biliary intervention (endoscopic, percutaneous, or surgical) following placement of C-SEMS vs U-SEMS for palliation of inoperable malignant distal bile duct obstruction.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

6 participants

Primary outcome timeframe

One year

Results posted on

2022-03-31

Participant Flow

Participants were recruited from patient population at the Vanderbilt Digestive Disease Center. Between November 8, 2017 until June 14, 2019, only 6 participants were randomized and completed the study.

4 participants screen failed before being randomized to either arm of the study. Only 6 participants was randomized (3 to each arm) and completed the study.

Participant milestones

Participant milestones
Measure
U-SEMS Group
Patients undergoing routine care ERCP and randomized to 10 mm diameter Uncovered Self-expanding metal biliary stents (U-SEMS) (Wallflex, Boston Scientific). Uncovered Self-expanding metal biliary stents (U-SEMS): Used for palliation of inoperable malignant distal bile duct obstructions.
C-SEMS Group
Patients undergoing routine care ERCP and randomized to a 10 mm diameter Covered Self-Expanding metal biliary stents (C-SEMS) (Wallflex, Boston Scientific) Covered Self-expanding metal biliary stents (C-SEMS): Used for palliation of inoperable malignant distal bile duct obstruction.
Overall Study
STARTED
3
3
Overall Study
COMPLETED
3
3
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
U-SEMS Group
n=3 Participants
Patients undergoing routine care ERCP and randomized to 10 mm diameter Uncovered Self-expanding metal biliary stents (U-SEMS) (Wallflex, Boston Scientific). Uncovered Self-expanding metal biliary stents (U-SEMS): Used for palliation of inoperable malignant distal bile duct obstructions.
C-SEMS Group
n=3 Participants
Patients undergoing routine care ERCP and randomized to a 10 mm diameter Covered Self-Expanding metal biliary stents (C-SEMS) (Wallflex, Boston Scientific) Covered Self-expanding metal biliary stents (C-SEMS): Used for palliation of inoperable malignant distal bile duct obstruction.
Total
n=6 Participants
Total of all reporting groups
Age, Continuous
73 Years
STANDARD_DEVIATION 0 • n=3 Participants
73 Years
STANDARD_DEVIATION 0 • n=3 Participants
73 Years
STANDARD_DEVIATION 0 • n=6 Participants
Sex: Female, Male
Female
0 Participants
n=3 Participants
3 Participants
n=3 Participants
3 Participants
n=6 Participants
Sex: Female, Male
Male
3 Participants
n=3 Participants
0 Participants
n=3 Participants
3 Participants
n=6 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
United States
3 participants
n=3 Participants
3 participants
n=3 Participants
6 participants
n=6 Participants

PRIMARY outcome

Timeframe: One year

Population: 3 participants randomized to each arm for a total of 6 participants. Of the 3 participants in the U-SEMS group, none needed repeat intervention. Of the 3 participants in the C-SEMS group, 2 needed repeat intervention.

Compare the rate of long-term stent failure, defined as need for repeat biliary intervention (endoscopic, percutaneous, or surgical) following placement of C-SEMS vs U-SEMS for palliation of inoperable malignant distal bile duct obstruction.

Outcome measures

Outcome measures
Measure
U-SEMS Group
n=3 Participants
Patients undergoing routine care ERCP and randomized to 10 mm diameter Uncovered Self-expanding metal biliary stents (U-SEMS) (Wallflex, Boston Scientific). Uncovered Self-expanding metal biliary stents (U-SEMS): Used for palliation of inoperable malignant distal bile duct obstructions.
C-SEMS Group
n=3 Participants
Patients undergoing routine care ERCP and randomized to a 10 mm diameter Covered Self-Expanding metal biliary stents (C-SEMS) (Wallflex, Boston Scientific) Covered Self-expanding metal biliary stents (C-SEMS): Used for palliation of inoperable malignant distal bile duct obstruction.
Rate of Long-term Stent Failure
0 Participants
2 Participants

SECONDARY outcome

Timeframe: One Year

Population: 3 participants randomized to each arm for a total of 6 participants. Of the 3 participants in the U-SEMS group, there were no reports of pancreatitis, cholangitis, cholecystitis, or perforation. Of the 3 participants in the C-SEMS group, there were no reports of pancreatitis, cholangitis, cholecystitis, or perforation.

Participants will be monitored for adverse stent-related or intervention-related outcomes such as pancreatitis, cholangitis, cholecystitis, perforation.

Outcome measures

Outcome measures
Measure
U-SEMS Group
n=3 Participants
Patients undergoing routine care ERCP and randomized to 10 mm diameter Uncovered Self-expanding metal biliary stents (U-SEMS) (Wallflex, Boston Scientific). Uncovered Self-expanding metal biliary stents (U-SEMS): Used for palliation of inoperable malignant distal bile duct obstructions.
C-SEMS Group
n=3 Participants
Patients undergoing routine care ERCP and randomized to a 10 mm diameter Covered Self-Expanding metal biliary stents (C-SEMS) (Wallflex, Boston Scientific) Covered Self-expanding metal biliary stents (C-SEMS): Used for palliation of inoperable malignant distal bile duct obstruction.
Rates of Adverse Stent-related or Intervention-related Outcomes
0 Participants
0 Participants

Adverse Events

U-SEMS Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 3 deaths

C-SEMS Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 2 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Sharee Burkeen, Research Program Manager

Vanderbilt University Medical Center

Phone: (615) 875-7515

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place